Theralase Technologies Inc.
TSX VENTURE : TLT

Theralase Technologies Inc.

August 18, 2011 08:30 ET

Theralase to Present Ground Breaking Scientific Study Results at Two International Conferences

TORONTO, ONTARIO--(Marketwire - Aug. 18, 2011) - Theralase Technologies Inc. (TSX VENTURE:TLT) announced today that it is presenting preclinical study results at two international scientific conferences.

At the first conference, the preclinical study will document the rapid detection of microorganisms, such as bacteria. At the second conference the preclinical study will explain how the proprietary Theralase technology activates the key inducible Nitric Oxide Synthase (iNOS) pathway. Dr. Lothar Lilge, a Professor in the Department of Medical Biophysics; University of Toronto will be delivering both presentations. These exciting studies highlight Theralase's commitment to advancing its exclusive patented technologies, which could lead to significant commercial advantages for the company.

The first conference will be held from August 17 to19, 2011 in Puebla, Mexico. Dr. Lilge will present at the International Commission on Optics on a "Technique for Rapid Microorganism Detection" developed as a partial result of Theralase's research and development of Theralase's patented Photo Dynamic Compounds (PDC) for the inactivation and destruction of microorganisms, such as bacteria. Photo Dynamic Compounds are light sensitive super molecules able to destroy cancerous cells, bacteria and viruses when light activated by Theralase's proprietary laser sources. The technique presented provides an opportunity for Theralase to augment its PDC inactivation research and development program with the means for the rapid detection of various types of bacteria in approximately 1 hour versus the current standards requiring typically 1 to 2 days.

At the second conference, Dr. Lilge will present at the North American Association of Laser Therapy (NAALT) at their 2011 Conference in Milwaukee, Wisconsin from September 22 to 24, 2011. The preclinical study by Theralase pertains to the mechanism of action of its 660 nm and 905 nm dual wavelength low level laser therapy (LLLT) and further explains how the proprietary Theralase technology activates the key inducible Nitric Oxide Synthase (iNOS) pathway. The research goes into detail to explain the importance of the iNOS pathway for accelerating the healing of tissue and why the Theralase dual wavelength technology is able to completely activate this key cellular pathway.

About Theralase Technologies Inc.

Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com or www.sedar.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Contact Information